alexa Oncovirotherapy of Glioblastoma

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Oncovirotherapy of Glioblastoma

Every year, approximately 3 to 5 of 100.000 people are newly diagnosed with a glioblastoma (GBM). The current standard of care is the surgical resection, radiotherapy and chemotherapy. However, despite this aggressive treatment, the median survival time is only 12 to 15 months after initial diagnosis. Patients with recurrent disease normally have a life expectancy of only a few weeks.

 

Citation: Naumann U, Holm PS (2015) Oncovirotherapy of Glioblastoma: A Kind of Immunotherapy? Brain Disord Ther S2:001.

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger